Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
Texas Heart Institute Journal · 2023
DOI: 10.14503/thij-21-7747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Texas Heart Institute Journal, 2023. Verfasst von Burak Can Depboylu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Mugla Sitki Kocman University Faculty of Medicine, Mugla, Turkey. Hauptthemen laut MEDLINE: Thromboangiitis Obliterans, Peripheral Arterial Disease, Diabetic Angiopathies, Atherosclerosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Cilostazol is a guideline-recommended drug that improves intermittent claudication and quality of life in patients with chronic atherosclerotic peripheral arterial disease. The drug is used for most etiologies of arterial occlusive diseases in clinical practice. This study aimed to evaluate whether patients benefit equally from cilostazol regardless of etiology.
Methods
Patients on cilostazol were divided into 4 groups according to arterial occlusive disease etiology: (1) atherosclerosis, (2) diabetic angiopathy, (3) embolism/thrombosis, and (4) Buerger disease. Patients' maximum walking distance, ankle-brachial index score and distal tissue oxygen saturation (Sto 2 ), clinical improvement onset time, ability to reach maximum benefit time, vascular surgeries, and wounds were compared before they started cilostazol and after 12 months. Results were evaluated at a statistical significance of P < .05.
Results
In 194 patients, 307 target extremities were evaluated in the 4 disease groups. After cilostazol use, maximum walking distance, ankle-brachial index score, and distal Sto 2 increased significantly in all groups ( P < .001), but distal Sto 2 in the diabetic angiopathy and Buerger disease groups was significantly lower than in the atherosclerosis group ( P < .001). Ankle-brachial index and distal Sto 2 differences in the Buerger disease group were significantly lower (both P < .001). The vascular surgery counts decreased significantly in the atherosclerosis and embolism/thrombosis groups ( P = .019 and P = .004, respectively).
Conclusion
Patients with nonatherosclerotic arterial occlusive disease also benefit from cilostazol, but patients with Buerger disease or diabetic angiopathy seem to benefit less. Combining cilostazol with anticoagulant or antiaggregant agents and closer monitoring of these patients may produce better results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Mugla Sitki Kocman University Faculty of Medicine, Mugla, Turkey.
Zitieren
APA
Can Depboylu, B., Yazman, S., Harmandar, B., Funda Tetik, M., Istar, H., Arslan, K., & Ilhan, G. (2023). Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?. Texas Heart Institute Journal. https://doi.org/10.14503/thij-21-7747
Vancouver
Can Depboylu B, Yazman S, Harmandar B, Funda Tetik M, Istar H, Arslan K, et al. Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?. Texas Heart Institute Journal. 2023. doi:10.14503/thij-21-7747
BibTeX
@article{CanDepboylu2023,
author = {Can Depboylu, Burak and Yazman, Serkan and Harmandar, Bugra and Funda Tetik, Muruvvet and Istar, Hande and Arslan, Kadir and Ilhan, Gokhan},
title = {Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?},
journal = {Texas Heart Institute Journal},
year = {2023},
doi = {10.14503/thij-21-7747}
}
EUVIMED